Acurx Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Acurx Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($1.99M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($2.25M) | Aug 11, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($2.25M) | Nov 12, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($2.15M) | Aug 11, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($2.15M) | Nov 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($2.15M) | May 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($2.82M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($4.12M) | Aug 11, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($4.12M) | Nov 12, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($4.38M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($4.38M) | May 12, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($4.38M) | Nov 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($3.11M) | Nov 12, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($3.45M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($3.45M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($2.90M) | May 14, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($2.90M) | Aug 8, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($2.90M) | Nov 12, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($3.54M) | Nov 13, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($2.62M) | Nov 13, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($2.03M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($2.27M) | Aug 11, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($2.83M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($4.12M) | Aug 11, 2025 |